E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with proven diagnosis of painful peripheral neuropathic pain syndromes as diagnosed as: 1. Peripheral nerve lesion or 2. Postherpetic neuralgia. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036376 |
E.1.2 | Term | Post herpetic neuralgia |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10034586 |
E.1.2 | Term | Peripheral nerve injury |
E.1.2 | System Organ Class | 10022117 - Injury, poisoning and procedural complications |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Aim of this trial is the assessment of the pain relief in patients suffering from peripheral neuropathic pain after treatment by topical application of lidocaine (5%).
|
|
E.2.2 | Secondary objectives of the trial |
- Other sensory profile alterations in patients after treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Included will be patients 18 years and older either genera with: -Proven Diagnosis of painful peripheral neuropathy for at least 3 months as diagnosed as: 1. Peripheral nerve lesion (i.e. pain within or adjacent to the area of nerve trauma or corresponding innervation territory or dermatome) or 2. Postherpetic neuralgia (Subjects with pain following herpes zoster with > 3 months after healing of herpes zoster skin rash). - At least moderate pain intensity under the current treatment. - Unchanged and stable pain medication within the last 4 weeks. - The patients have to display some remaining sensory function at the baseline QST. - Intact skin in the area of lidocaine medicated plaster application. - Females with childbearing potential must be using adequate contraception. - Women of childbearing potential must have a negative urine ß-human chorionic gonadotropin (ß-HCG) pregnancy test.
|
|
E.4 | Principal exclusion criteria |
Excluded will be patients with: - History of current alcohol or drug abuse. - Any scheduled surgery of painful procedure during the course of the trial. - Presence of a disease that affects the subject’s compliance. - Use of any topical anaesthetics in the area of pain within the last 6 months. - Use of capsaicin (low or high-dose) in the area of pain within the last 6 months. - Use of TENS within the area of pain in the last 4 weeks. - Subjects who had nerve ablation by block or neurosurgical intervention for pain treatment at the affected area. - Evidence or another cause of pain within the area of pain or another severe pain condition that may interfere with the trial aims or procedures. - Severe loss of sensory function - Contraindications or hypersensitivity to local anaesthetics of amide type or to any of the exipients. - Intake of class I antiarrhythmic drugs (e.g. tocainide, mexilitine). - Use of systemically applied local anaesthetics within the last 4 weeks - Active herpes zoster lesion, dermatitis or skin lesions of any origin within the area of pain. - Clinically relevant cardiac insufficiency (NYHA Class III to IV) - Clinical relevant severe impairment of the kidney or liver function
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- The amount of pain relief (NRS-3) - Number of treatment responders (as defined as subjects with a decrease of average pain (NRS-3) by > 30% at Visit 3 and Visit 5). - Decrease of A-delta- and C-fiber function after treatment using topical application of lidocaine (5%) or placebo. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
NRS-3 at Visit 3 (day 21) and Visit 5 (day 42) compared to baseline NRS-3 at Visit 2 (day 7) and 4 (day 24) |
|
E.5.2 | Secondary end point(s) |
- Changes of other QST parameters (tactile detection thresholds, thermal or mechanical hyperalgesia, dynamic mechanical allodynia). - To assess the symptom intensity and their possible changes after application of lidocaine (5%) the PainDETECT and NPSI (German version) questionnaire will be used at baseline and at each obligatory follow-up, the Patient Global Impression of Change scale (PGIC) will be used as a non-specific tool as well. - During the treatment a patient’s diary including the current, average and maximum pain intensity will be documented as well the intensity of some other complaints (e.g. nausea, drowsiness, sleep disorder etc.). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
- Subject withdraws his/her informed written consent. - Serious or severe adverse event occuring under study treatment. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 12 |